Form 4: TriSalus Life Sciences Director, David J. Matlin, Reports Change in Beneficial Ownership Due to Series A Preferred Stock Conversion Price Reset

Sentiment:

SEC Form 4 Filing


David J. Matlin, a director of TriSalus Life Sciences, reported a change in beneficial ownership on February 10, 2025, due to a reset in the conversion price of Series A Convertible Preferred Stock, leading to an increase in the number of common shares issuable upon conversion.

Summary

  • On February 10, 2025, David J. Matlin, a director of TriSalus Life Sciences, reported a change in beneficial ownership.
  • The change is due to a reset in the conversion price of the company's Series A Convertible Preferred Stock.
  • The conversion price was reset to $5.277 per share, effective February 10, 2025, according to the terms outlined in the Certificate of Designations filed on August 10, 2023.
  • This reset resulted in an increase in the number of common shares issuable upon conversion of the preferred stock.
  • Matlin holds 100,000 shares of Series A Convertible Preferred Stock, which are now convertible into 189,501 shares of common stock.
  • This represents an incremental increase of 89,501 shares of common stock issuable due to the conversion price reset.
  • All outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing related to a conversion price reset. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about a change in beneficial ownership. The reset itself is a contractual obligation, so it's a neutral event.

Future Outlook

The Series A Preferred Stock is convertible into Common Stock at any time at the Reporting Person's election, and all outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates a change in the number of shares issuable upon conversion of preferred stock, which is a fairly common event tied to the terms of the preferred stock agreement.

Key Dates

DateDescription
August 10, 2023Date of filing of the Issuer's Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock with the Delaware Secretary of State.
February 10, 2025Date of the conversion price reset for the Series A Convertible Preferred Stock.
February 11, 2025Date of signature of the Form 4 filing.
August 10, 2027Date of automatic conversion of all outstanding shares of Preferred Stock into shares of the Issuer's Common Stock.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.